HomeFile

File

View Category
Coronary disease

ABSORV at Long Term in Daily Practice Lesions

This work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety...
solaci -
Learn More
Structural heart disease

SAPIEN 3: Low One-Year-Mortality in High Risk or Inoperable Patients

In the first PARTNER trial (Placement of Aortic Transcatheter Valves), mortality at one year was 24% for...
solaci -
Learn More
Other

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful...
solaci -
Learn More
Antiplatelet

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that...
solaci -
Learn More
Structural heart disease

Bivalirudin or Heparin to Decrease Cerebral Embolization Post TAVI?

  Cerebral embolization is a relatively frequent complication during transcatheter aortic valve replacement (TAVR). The hypothesis behind this...
solaci -
Learn More
Aorta

TAAA: Better Outcomes with Renal Fenestration

Courtesy of Dr. Carlos Fava.   Thoraco-abdominal aneurysms (TAAA) are a real challenge for surgeons. So far, endovascular repair...
solaci -
Learn More
Antiplatelet

Optimal Duration of DAPT: How to Predict Long-Term Events

Courtesy of Dr. Santiago F. Coroleu.   Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention...
solaci -
Learn More
Acute coronary syndromes

Closure Devices vs. Manual Compression

Courtesy of Dr. Guillermo Migliaro.   Post PCI major bleeding has been associated with short term mortality in acute...
solaci -
Learn More